New hope for Tough-to-Treat colorectal cancer? drug trial uses ultrasound to predict success
NCT ID NCT04355156
First seen Apr 24, 2026 · Last updated Jun 14, 2026 · Updated 9 times
Summary
This study tested a drug called axitinib against a placebo in 52 people with advanced colorectal cancer that had spread to the liver and stopped responding to chemotherapy. The goal was to see if axitinib could help control the cancer and to test a special ultrasound technique that measures blood flow to tumors to predict how well a patient might respond. The trial is complete, and results focus on survival differences between those whose tumors showed a blood flow reduction and those who did not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.